Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | ILK | Q13418 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468797 | 0.75 | — | — | |
| SCHEMBL14307558 | 0.71 | MAPK14 (0.40) | ACHEMAPK14 | |
| SCHEMBL7829346 | 0.69 | AKT2 (0.44) | ALDH1A1 | |
| SCHEMBL14519431 | 0.66 | MAPK14 (0.44) | CSNK1DCSNK1EMAPK14ILK | |
| SCHEMBL16473172 | 0.65 | LMNA (0.38) | — | |
| SCHEMBL9275778 | 0.65 | PARP1 (0.35) | ALDH1A1PARP1 | |
| SCHEMBL29410050 | 0.65 | PARP1 (0.35) | ALDH1A1PARP1 | |
| SCHEMBL31399825 | 0.65 | TDP1 (0.41) | ALDH1A1 | |
| SCHEMBL17424258 | 0.63 | LTA4H (0.42) | PDE10AALDH1A1 | |
| SCHEMBL13102550 | 0.63 | CYP11B1 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969556-B2 | Purine-based triazoles | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045866-A1 | PURINE-BASED TRIAZOLES | CASE WESTERN RESERVE UNIVERSITY | 2014-02-13 | — | — | US | disclosed |
| WO-2012051296-A2 | PURINE-BASED TRIAZOLES | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045866-A1 | PURINE-BASED TRIAZOLES | PNP, TK2, NME4 | ACHE 4365/4885PDE2A 786/4885PDE10A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.